Vertinex Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Prochlorperazine maleate

Indications/Uses

Vertigo due to Meniere's syndrome, labyrinthitis & other causes; nausea & vomiting from whatever cause including that associated w/ migraine. Chronic stage schizophrenia, acute mania. Adjunct to short management of anxiety.

Click to view Vertinex detailed prescribing information

Dosage/Direction for Use

Adult Prevention of nausea & vomiting 5-10 mg bid-tid. Treatment of nausea & vomiting 20 mg stat followed by 10 mg after 2 hr if necessary. Vertigo & Meniere's syndrome 5 mg tid, may be increased to 30 mg daily, & may be reduced gradually to 5-10 mg daily after several wk. Adjunct in short term management of anxiety Initially 15-20 mg daily in divided doses, may be increased to max of 40 mg daily in divided doses if necessary. Schizophrenia & other psychotic disorders Usual effective dose: 75-100 mg daily. Initially 12.5 mg bid for 7 days, may be increased at 4-7 days. Childn 0.25 mg/kg bid-tid.

Click to view Vertinex detailed prescribing information

Overdosage

View Vertinex overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Vertinex detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Vertinex detailed prescribing information

Special Precautions

Avoid in patients w/ liver or renal dysfunction, Parkinson's disease, hypothyroidism, cardiac failure, pheochromocytoma, myasthenia gravis & prostate hypertrophy; hypersensitivity to phenothiazine or w/ history of narrow angle glaucoma or agranulocytosis. Acute w/drawal symptoms including nausea, vomiting & insomnia. Gradual w/drawal is advised. May potentiate QT interval prolongation. Patients w/ stroke risk factors; depression. Avoid exposure to direct sunlight. Closely monitor patients w/ epilepsy or history of seizure. Regularly monitor CBC. NMS. VTE. Hyperglycemia or intolerance to glucose. Perform medical & lab evaluations before & during initial phase of treatment. Depression skin reactions. Hyperglycemia. Avoid concomitant treatment w/ other neuroleptics. May affect ability to drive or operate machines. Pregnancy. Suspend breastfeeding during treatment. Not recommended in childn <10 kg or <1 yr. Elderly. Increased mortality in elderly people w/ dementia

Click to view Vertinex detailed prescribing information

Use In Pregnancy & Lactation

Click to view Vertinex detailed prescribing information

Adverse Reactions

Acute dystonia or dyskinesias (in childn & young adult); akathisia; parkinsonism (in adult & elderly); tardive dyskinesia; insomnia; agitation; convulsions.

Click to view Vertinex detailed prescribing information

Drug Interactions

Intensified effects & resp depression may occur w/ alcohol, barbiturates & other sedatives. May reduce antipsychotic effects w/ anticholinergics. May interfere absorption w/ antacids, anti-Parkinson drugs & lithium. Antagonized antiparkinsonian action of dopaminergic. High doses may reduce the response to hypoglycemic agents. May exaggerate the hypotensive effects of α-adrenoceptor blocking agents. Opposed effects w/ amphetamine, L-dopa, clonidine, guanethidine & adrenaline. Induce transient metabolic encephalopathy characterised by loss of consciousness w/ desferrioxamine & prochlorperazine. Increased risk of arrhythmia w/ QT prolonging drugs & drugs causing electrolyte imbalance. Risk of agranulocytosis w/ drugs w/ myelosuppressive potential eg, carbamazepine, certain antibiotics & cytotoxics. Pharmacokinetic interaction between CYP2D6 inhibitors & substrates. May increase plasma levels of amitriptyline/amitriptylinoxide.

Click to view Vertinex detailed prescribing information

Storage

View Vertinex storage conditions for details to ensure optimal shelf-life.

Description

View Vertinex description for details of the chemical structure and excipients (inactive components).

Action

View Vertinex mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antipsychotics / Antiemetics / Antivertigo Drugs

ATC Classification

N05AB04 - prochlorperazine ; Belongs to the class of phenothiazine antipsychotics with piperazine structure.

Regulatory Classification

Presentation/Packing

Form

Vertinex tab 5 mg

Packing/Price

50's (P618/box)

Vertinex

prochlorperazine

Manufacturer:

Kusum Healthcare

Distributor:

Kusum Healthcare